We’re on pause this week as we have our heads down on some longer-term projects that we look forward to sharing with you in due course.
If you’re yearning for something to read from us, some recent longer pieces include:
- Last week’s deep dive into a DMT therapy study that had a notable lack of attention to managing set and setting.
- The May Psychedelic Research Bulletin, powered by our friends at Blossom.
- Our analysis of MindMed’s Phase 2 LSD for Anxiety study results that we published last month (readers may enjoy reading this alongside Erik Davis’ long-ish, The Elephant LSD, which provides a very different perspective).
We’re also launching an Opinions column, so perhaps you can spend the time that you would have spent reading our Bulletin to mull over a proposal or two…
Call for Submissions: Opinions
We’re looking to present a variety of viewpoints on psychedelic medicine via a forthcoming Opinions column.
We expect these viewpoint pieces to be no longer than 1,000 words. We’re flexible in terms of form and substance.
Should you wish to be considered, please fill out the form.
Featured Psychedelic Jobs
How to Change Your Mind: Netflix
Michael Pollan’s best-selling book, How to Change Your Mind, has been adapted into a four-part Netflix series that will first air on July 12th.
The trailer was released earlier this week:
More from our Twitter
- Would you take MDMA to save your marriage? (via The Telegraph)
- The 18 power players shaping the future of Oregon’s psilocybin market (via Business Insider)
- How magic mushrooms could revolutionise care homes (via the Telegraph)
- “The Times: Change is coming, even if it’s slow. Hold on to your hats, people. Psychedelics are about to go mainstream.”
Join our newsletter to have our Weekly Bulletin delivered to your inbox every Friday evening. We summarise the week’s most important developments and share our Weekend Reading suggestions.